DOCSLIB.ORG

SARS-Cov-2 Vaccine Development: Where Are We?

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
SARS-Cov-2 Vaccine Development: Where Are We? European Review for Medical and Pharmacological Sciences 2021; 25: 2752-2784 SARS-CoV-2 vaccine development: where are we? M. GALDIERO1, M. GALDIERO1, V. FOLLIERO1, C. ZANNELLA1, A. DE FILIPPIS2, A. MALI1, L. RINALDI3, G. FRANCI4 1Department of Experimental Medicine, University of Campania “Luigi Vanvitelli”, Naples, Italy 2Department of Pharmacy, University of Study of Naples “Federico II”, Naples, Italy 3Department of Advanced Medical and Surgical Sciences, University of Campania “Luigi Vanvitelli”, Naples, Italy 4Department of Medicine, Surgery and Dentistry “Scuola Medica Salernitana”, University of Salerno, Salerno, Italy Abstract. – The coronavirus disease 2019 in many remarkable traits from all other positive (COVID-19) pandemic caused by severe acute re- single-stranded RNA viruses: i) their RNA ge- spiratory syndrome coronavirus 2 (SARS-CoV-2) nomes are substantially larger than the genomes has proved to be one of the most challenging in- of any other known positive-stranded RNA virus; fectious diseases in the modern era, and despite several countermeasures to lessen its impact, the ii) coronaviruses are unique in showing a heli- spread of the virus is still affecting most countries. cal symmetry of the nucleocapsid; and doubtless This renders the goal of active immunization of the most peculiar, iii) coronaviruses replicate their population through vaccination a worldwide pub- positive-stranded RNA genomes by a strategy in lic health priority. In fact, only when efficient vac- which they give rise to a nested set of messenger cination programs will be successfully implement- RNAs (mRNAs) that have a common 3’ end. Each ed, a return to pre-pandemic normality can be considered. The scientific community has made of the mRNAs within the nested set contains mul- a tremendous effort to blow the lid off the patho- tiple open reading frames (ORFs), where only the 1 genesis of the disease, and unprecedented efforts one at the 5’ end of the molecule is translated . are ongoing with governments, private organiza- This family of RNA viruses, though almost un- tions, and academics working together to expe- known to the large audience until recently, has ditiously develop safe and efficacious vaccines. been the object of extensive studies by scientists Previous research efforts in the development of in the last few decades. Prior to 2003, only two vaccines for other coronaviruses (Severe Acute Respiratory Syndrome Coronavirus 1 and Middle strains of coronavirus, the Human coronavirus East Respiratory Syndrome Coronavirus) as well (HcoV) 229E and HCoV-OC43, were associat- other emerging viruses have opened the door for ed with a mild influenza-like illness in humans. exploiting several strategies to design a new vac- Hence, researchers in the field were taken by cine against the pandemic virus. Indeed, in a few surprise in 2003 when it was discovered that the months, a stunning number of vaccines have been causative agent for the new severe acute respira- proposed, and almost 50 putative vaccine can- didates have entered clinical trials. The different tory syndrome (SARS) epidemic was identified as vaccine candidates use different vaccine develop- a “new” coronavirus. The discovery of the SARS ment platforms, from inactivated whole virus vac- coronavirus (SARS-CoV) stimulated extensive cine to subunit vaccine, nucleic acid, and vectored research in the field of coronaviruses, as regards vaccines. In this review, we describe strengths, the molecular mechanisms necessary for the defi- flaws, and potential pitfalls of each approach to nition of target molecules, the development of understand their chances of success. antivirals and/or vaccines, and the identification Key Words: of other novel coronaviruses in both humans and SARS-CoV-2, COVID-19, Vaccine, Pandemic, Im- animals, leading to the discovery of two other mune response. coronaviruses that infect humans: HCoV-NL63 in 2004 and HCoV-HKU1 in 20052. Unlike other human coronaviruses, SARS-CoV was capable of Introduction causing severe and life-threatening pneumonia in humans and was the most pathogenic coronavirus Coronaviridae are a very intriguing family of until a further coronavirus capable of causing fa- positive single-stranded RNA viruses. They differ tal disease in humans, the Middle East respiratory 2752 Corresponding Author: Massimiliano Galdiero, MD; e-mail: [email protected] SARS-CoV-2 vaccine development: where are we? syndrome coronavirus (MERS-CoV), appeared. against SARS-CoV-2. Moreover, it delves into the Finally, to complete the picture of coronavirus- composition of the different vaccine platforms and es of human interest, a disease, named Corona- the relative advantages and/or disadvantages of virus Disease 2019 (COVID-19), came to light in each approach. Wuhan, within the Hubei Province in China, in early December 2019, but in a flash, a pandem- Viral Structural Proteins ic magnitude was reached. As of 29th November and their Function 2020, a total number of 61,869,330 confirmed cas- SARS-CoV-2 particles contain a posi- es of COVID-19 have been reported, including tive-strand RNA genome of 29.9 kb in length. 1,448,896 deaths3. Caused by severe acute respi- The genome is both capped and poly-adenylated, ratory syndrome coronavirus 2 (SARS-CoV-2), enabling SARS-CoV-2 to be translated upon its the pandemic represents a serious threat to public release within the cytoplasm right at the begin- health since infection leads to a wide spectrum ning of an infectious cycle. of clinical manifestations with an initial status The SARS-CoV-2 genome possess 14 ORFs of the asymptomatic subject, with progression to encoding 27 proteins, and its genomic organi- pneumonia which may further progress to acute zation follows the common rules of other coro- respiratory distress syndrome (ARDS) followed naviruses being: 5′-leader-UTR-replicase-Spike by multi-organ failure (MOF) and death4. While (S)-Envelope (E)-Membrane (M)-Nucleocapsid the last three viruses with high pathogenicity and (N)-3′UTR-poly(A)tail, with several accessory mortality (SARS-CoV, MERS-CoV, and SARS- genes interspersed within the structural genes at CoV-2) have only recently emerged in the hu- the 3′ end of the genome7. The accessory genes man population, HCoV-HKU1 and HCoV-NL63 are considered nonessential for in vitro replication have been circulating in humans for a long time. but able to exert a suppressing effect on the anti- HCoV-HKU1 and HCoV-NL63 are both respira- viral-immune responses and also able to intensify tory coronaviruses that are frequently associated pathogenesis8. A large portion of about two-thirds with upper and lower respiratory tract diseases. of the genome within the 5′ end is employed to Infections with these two human coronaviruses encode two long ORFs named 1a and 1b, which do not differ much from those caused by the “old” produce the nonstructural proteins of the virus. coronaviruses HCoV-229E and HCoV-OC43. Orfs 1a and 1b are translated first as polyprotein The first severe acute respiratory syndrome due precursors named pp1a and pp1ab, where the to SARS-CoV spanned the world with more than latter results from a programmed –1 ribosomal 8,000 recognized cases and caused 774 deaths frameshift event taking place at the short overlap (almost 9% of infected cases) in less than a year at the end of ORF1a with ORF1b coding sequenc- and then disappeared5. The second outbreak in es9. The polyproteins include several viral prote- 2012, MERS-CoV, remained mainly localized in ases that together process pp1a and pp1ab into 16 the Arabic peninsula, where 1,038 cases with 460 nonstructural proteins (nsp1–16), which are sub- deaths were reported (approximately 37% mortali- sequently required at diverse phases of SARS- ty). Since then, it reappeared with small epidemics CoV-2 replication. From a morphological point of mainly nosocomial infections in South Korea6. of view of the virus particles, the SARS-CoV-2 On the other hand, the present pandemic has swept genome is associated with the N protein to form the surface of the globe with an unprecedented and a helical nucleocapsid, which in turn is wrapped unforecastable spreading capacity, albeit with mi- by a lipid membrane envelope containing the M, nor mortality compared to the previous two, and S, and E proteins (Figure 1). The trimeric S gly- is still in a crescendo after almost a year from its coprotein (∼150 kDa) is the largest membrane emergence in the human population. As seen in the protein forming 20 nm-long and prominent pet- actual situation, we need to accept that the SARS- al-shaped spikes and is involved in cell receptor CoV-2 will remain a treat for a long time. There- binding of the virus to the host cell and in mediat- fore, the best option for getting back to our usual ing the fusion mechanism able to allow the entry social life (considering the measures adopted by of the virus into cells. most Governments worldwide of social distancing The S glycoprotein is a class I fusion protein and more or less strict lockdowns) is represented whose attachment to the host receptor angioten- by the widespread distribution and use of vaccines. sin-converting enzyme 2 (ACE2) is able to trigger This review addresses the key point of the immune a cascade of cell membrane fusion events lead- responses deemed essential to provide protection ing to viral entry10-13. Glycoprotein S is further 2753 M. Galdiero, M. Galdiero, V. Folliero, C. Zannella, A. De Filippis, A. Mali, L. Rinaldi, G. Franci Figure 1. Vaccine platforms used for SARS-CoV-2 vaccine development. cleaved by a host cellular protease into two sep- protein is to be found in its function in promoting arate polypeptides: a globular S1 domain at the membrane curvature as well as binding to the nu- N-terminal region, and the membrane-proximal cleocapsid; therefore, M protein fulfills the func- S2 and transmembrane domains14.
Load more

Recommended publications
  • RNA-Based Adjuvant CV8102 Enhances the Immunogenicity of a Licensed Rabies Vaccine in a first-In-Human Trial
    Vaccine 37 (2019) 1819–1826 Contents lists available at ScienceDirect Vaccine journal homepage: www.elsevier.com/locate/vaccine RNA-based adjuvant CV8102 enhances the immunogenicity of a licensed rabies vaccine in a first-in-human trial Fatma Doener a,1, Henoch S. Hong a,1, Ingo Meyer b,1, Keyvan Tadjalli-Mehr c, Angelika Daehling c, ⇑ Regina Heidenreich a, Sven D. Koch a, Mariola Fotin-Mleczek a, Ulrike Gnad-Vogt c, a Curevac AG, Paul-Ehrlich-Strasse 15, 72076 Tübingen, Germany b CRS Clinical Research Services Mönchengladbach GmbH, 41061 Mönchengladbach, Germany c Curevac AG, Schumannstrasse 27, 60325 Frankfurt, Germany article info abstract Article history: Background: We report the first-in-concept human trial of the safety, tolerability and immunogenicity Received 27 September 2018 when a novel TLR 7/8/RIG I agonist RNA-based adjuvant, CV8102, was administered alone or mixed with Received in revised form 30 January 2019 fractional doses of a licensed rabies vaccine (RabipurÒ) as model antigen. Accepted 3 February 2019 Methods: The primary objective was to assess the safety and reactogenicity of various dose levels of Available online 21 February 2019 CV8102 alone or mixed with RabipurÒ in healthy 18–40 year-old male volunteers. A secondary objective was to assess the immune-enhancing potential of bedside-mixes of CV8102 with fractional doses of Keywords: Ò Rabipur by measuring induction of rabies virus neutralising titres (VNTs). Adjuvant Results: Fifty-six volunteers received 50–100 lg CV8102 alone (n = 11), bedside-mixed CV8102 and RNA Ò Ò Ò Rabies Rabipur (n = 20), or Rabipur alone (n = 25; control).
    [Show full text]
  • Immunogenicity of Clinically Relevant SARS-Cov-2 Vaccines
    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 7 September 2020 1 Immunogenicity of clinically relevant SARS-CoV-2 vaccines in non-human primates and humans P. J. Klasse (1,*), Douglas F. Nixon (2,*) and John P. Moore (1,+) 1 Department of Microbiology and Immunology; 2 Division of Infectious Diseases, Department of Medicine, Weill Cornell Medical College, New York, NY 10065 *These authors contributed equally +Correspondence: [email protected] Short title: SARS-CoV-2 vaccine immunogenicity Key words: SARS-CoV-2, S-protein, RBD, COVID-19, neutralizing antibodies, serology, T- cells, vaccines, animal models, Operation Warp Speed © 2020 by the author(s). Distributed under a Creative Commons CC BY license. Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 7 September 2020 2 Abstract Multiple preventive vaccines are being developed to counter the COVID-19 pandemic. The leading candidates have now been evaluated in non-human primates (NHPs) and human Phase 1 and/or Phase 2 clinical trials. Several vaccines have already advanced into Phase 3 efficacy trials, while others will do so before the end of 2020. Here, we summarize what is known of the antibody and T-cell immunogenicity of these vaccines in NHPs and humans. To the extent possible, we compare how the vaccines have performed, taking into account the use of different assays to assess immunogenicity and inconsistencies in how the resulting data are presented. We also summarize the outcome of SARS-CoV-2 challenge experiments in immunized macaques, while noting variations in the protocols used, including but not limited to the virus challenge doses. Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 7 September 2020 3 Introduction The COVID-19 pandemic rages unabated and may continue to do so until there is a safe, effective and widely used protective vaccine.
    [Show full text]
  • SARS-Cov-2 RBD219-N1C1 Was Diluted in 20 Mm Tris, 150 Mm Nacl, Ph 7.5 (TBS Buffer) Before
    bioRxiv preprint doi: https://doi.org/10.1101/2020.11.04.367359; this version posted November 5, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Title Page SARS‑CoV-2 RBD219-N1C1: A Yeast-Expressed SARS-CoV-2 Recombinant Receptor-Binding Domain Candidate Vaccine Stimulates Virus Neutralizing Antibodies and T-cell Immunity in Mice 1 2 3 Jeroen Pollet1,2, Wen-Hsiang Chen1,2, Leroy Versteeg1, Brian Keegan1, Bin Zhan1,2, Junfei 4 Wei1, Zhuyun Liu1, Jungsoon Lee1, Rahki Kundu1, Rakesh Adhikari1, Cristina Poveda1, 5 Maria-Jose Villar Mondragon1, Ana Carolina de Araujo Leao1, Joanne Altieri Rivera1, Portia 6 M. Gillespie1, Ulrich Strych1,2, Peter J. Hotez1,2,3,4,*, Maria Elena Bottazzi1,2,3* 7 1 Texas Children’s Hospital Center for Vaccine Development, Houston, TX, USA 8 2 Departments of Pediatrics and Molecular Virology & Microbiology, National School of Tropical 9 Medicine, Baylor College of Medicine, Houston, TX, USA 10 3 Department of Biology, Baylor University, Waco, TX, USA 11 4 James A. Baker III Institute for Public Policy, Rice University, Houston, TX, USA 12 * Correspondence: 13 Corresponding Authors 14 [email protected]; [email protected] 15 16 bioRxiv preprint doi: https://doi.org/10.1101/2020.11.04.367359; this version posted November 5, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Yeast-expressed SARS-CoV-2 RBD 17 Abstract 18 There is an urgent need for an accessible and low-cost COVID-19 vaccine suitable for low- and 19 middle-income countries.
    [Show full text]
  • An Update Review of Globally Reported SARS-Cov-2 Vaccines in Preclinical and Clinical Stages
    International Immunopharmacology 96 (2021) 107763 Contents lists available at ScienceDirect International Immunopharmacology journal homepage: www.elsevier.com/locate/intimp Review An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages Hamid Motamedi a, Marzie Mahdizade Ari b, Shirin Dashtbin b, Matin Fathollahi a, Hadi Hossainpour a, Amirhoushang Alvandi a,c, Jale Moradi a, Ramin Abiri a,d,* a Department of Microbiology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran b Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran c Medical Technology Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran d Fertility and Infertility Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran ARTICLE INFO ABSTRACT Keywords: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the rapidly spreading COVID-19 pandemic COVID-19 in the world. As an effective therapeutic strategy is not introduced yet and the rapid genetic SARS-CoV-2 variations in the virus, there is an emerging necessity to design, evaluate and apply effective new vaccines. An Vaccines acceptable vaccine must elicit both humoral and cellular immune responses, must have the least side effects and the storage and transport systems should be available and affordable for all countries. These vaccines can be classified into different types: inactivated vaccines, live-attenuated virus vaccines, subunit vaccines, virus-like particles (VLPs), nucleic acid-based vaccines (DNA and RNA) and recombinant vector-based vaccines (repli­ cating and non-replicating viral vector). According to the latest update of the WHO report on April 2nd, 2021, at least 85 vaccine candidates were being studied in clinical trial phases and 184 candidate vaccines were being evaluated in pre-clinical stages.
    [Show full text]
  • A Step Towards Revising the Model for Vaccine Tuberculosis Immunity
    COMMENTARY CONTEST Revising the model for vaccine development: a step towards tuberculosis immunity Amy Dagenais1 1University of Ottawa, Ottawa, Ontario, Canada Date Published: August 26, 2021 DOI: https://doi.org/10.18192/UOJM.V11iS1.5929 Keywords: Tuberculosis, COVID-19, vaccines hanks to accelerated vaccine development, the first with the largest infectious disease burden in the world, COVID-19 vaccine was approved for use by Health tolling 10 million new infections and 1.2 million deaths Canada only nine months after the disease was in 2019 alone.² Indeed, tuberculosis is one of the top 10 Tdeclared a pandemic by the World Health Organization.¹ causes of death worldwide—but the situation remains This unprecedented feat was made possible by three underdiscussed as most cases are recorded in developing critical factors: a stressed sense of urgency, substantial areas, such as South-East Asia (44%) and Africa (25%), or funding, and parallel pre-clinical and clinical trials. Such in underserved populations such as the Inuit in Canada.2,3 a concerted effort not only led to the development of Approximately one-quarter of the world population is multiple effective vaccines, but also bred innovation as infected by the etiological agent of tuberculosis: the mRNA technology bloomed despite its limited use in the bacterium Mycobacterium tuberculosis (Mtb), known as past. This success story paves the way for the accelerated the most successful human pathogen.² development of vaccines for other diseases, such as tuberculosis—the deadliest infectious disease of modern The intracellular pathogen has co-evolved with humans times before COVID-19 emerged. to evade host immune defenses, rendering TB treatment particularly difficult.
    [Show full text]
  • Yellow Fever Vaccine See Hojas De Información Sobre Vacunas Están Disponibles En Español Y En Muchos Otros What You Need to Know Idiomas
    VACCINE INFORMATION STATEMENT Many Vaccine Information Statements are available in Spanish and other languages. Yellow Fever Vaccine See www.immunize.org/vis Hojas de información sobre vacunas están disponibles en español y en muchos otros What You Need to Know idiomas. Visite www.immunize.org/vis 1 What is yellow fever? 3 Yellow fever vaccine Yellow fever is a serious disease caused by the yellow Yellow fever vaccine is a live, weakened virus. It is fever virus. It is found in certain parts of Africa and given as a single shot. For people who remain at risk, a South America. booster dose is recommended every 10 years. Yellow fever is spread through the bite of an infected Yellow fever vaccine may be given at the same time as mosquito. It cannot be spread person to person by direct most other vaccines. contact. Who should get yellow fever vaccine? People with yellow fever disease usually have to be • Persons 9 months through 59 years of age traveling hospitalized. Yellow fever can cause: to or living in an area where risk of yellow fever is • fever and flu-like symptoms known to exist, or traveling to a country with an entry • jaundice (yellow skin or eyes) requirement for the vaccination. • bleeding from multiple body sites • Laboratory personnel who might be exposed to yellow • liver, kidney, respiratory and other organ failure fever virus or vaccine virus. • death (20% - 50% of serious cases) Information for travelers can be found online through CDC (www.cdc.gov/travel), the World Health 2 How can I prevent yellow fever? Organization (www.who.int), and the Pan American Health Organization (www.paho.org).
    [Show full text]
  • Recombivax HB , YF-Vax – Drug Shortages
    Recombivax HB®, YF-Vax® – Drug shortages • The drug shortages of Recombivax HB (hepatitis B vaccine, recombinant) and YF-Vax (yellow fever virus strain 17d-204 live antigen) are ongoing. Recombivax HB and YF-Vax have been unavailable for at least 90 days. Product Description NDC # Recombivax HB (hepatitis B vaccine, recombinant) 0.5 mL (5 mcg) 0006-4981-00, 0006- pediatric/adolescent formulation 4093-02, 0006-4093-09 single-dose vials and prefilled syringes Recombivax HB (hepatitis B vaccine, 0006-4995-00, 0006- recombinant) 1 mL (10 mcg) adult 4995-41, 0006-4094-02, formulation single-dose vials and 0006-4094-09 prefilled syringes YF-Vax (yellow fever virus strain 17-d- 49281-0915-01, 49281- 2014 live antigen) single- and multi- 0915-05 dose vials — The shortage of Recombivax HB is due to increased global demand. — The Recombivax HB pediatric/adolescent and adult formulations are estimated to be available in the first half of 2018 and the first half of 2019, respectively. — The Recombivax HB dialysis formulation is available; however, the dose is different than the adult and pediatric/adolescent formulations. — YF-Vax is unavailable because the manufacturer, Sanofi Pasteur, is transitioning production to a new facility in 2018. YF-Vax is estimated to be available by mid-2018. • Recombivax HB is indicated for prevention of infection caused by all known subtypes of hepatitis B virus. — Engerix-B™ (hepatitis B vaccine, recombinant) is another currently available vaccine that carries the same indication as Recombivax HB. Engerix-B is not in shortage. — Heplisav-B™ (hepatitis B vaccine, recombinant) was recently approved and carries the same indication as Recombivax HB.
    [Show full text]
  • Will We Be Able to Achieve Herd Immunity Against COVID-19?
    35 Will We Be Able to Achieve Herd Immunity Against COVID-19? Series | COVID-19 & response strategy Authors: Clara Marín, Oriana Ramírez, Carlota Dobaño, Jeffrey V Lazarus, Gemma Moncunill and Adelaida Sarukhan (ISGlobal)* [ This document is a one On 10 May 2021, the Spanish prime defines herd immunity as “the indirect of a series of discussion minister announced that, if the vaccine protection from an infectious disease that notes addressing delivery schedule is met, Spain would happens when a population is immune fundamental questions reach the government’s desired level of either through vaccination or immunity about the COVID-19 herd immunity—70% of the population developed through previous infection”2. crisis and response vaccinated—in 100 days, i.e. on 18 Au- Since the start of the pandemic, the pos- strategies. These gust1. Given the available evidence, is this sibility of achieving herd immunity documents are based claim realistic? has been touted as a way to avoid shut- on the best scientific ting down the economy or accelerate its Since COVID-19 was declared a pan- information available re-opening. However, this proved to be a demic in March 2020, our societies have and may be updated as double-edged sword. Countries such as undergone profound changes, starting new information comes Sweden and the United Kingdom tried to light.] with government-imposed restrictions on to base their strategy on achieving early fundamental rights such as freedom of herd immunity by allowing a majority of movement and freedom of assembly. An the population to become infected. These effective vaccine against SARS-CoV-2 strategies were either rectified, as in the was seen as the great hope for a way out United Kingdom, or mortality increased of the health and economic crisis caused by 11 June 2021 to an unjustifiable extent, as in Sweden.
    [Show full text]
  • Inhibition of HIV-1 by an Anti-Integrase Single-Chain Variable
    Gene Therapy (1999) 6, 660–666 1999 Stockton Press All rights reserved 0969-7128/99 $12.00 http://www.stockton-press.co.uk/gt Inhibition of HIV-1 by an anti-integrase single-chain variable fragment (SFv): delivery by SV40 provides durable protection against HIV-1 and does not require selection M BouHamdan1, L-X Duan1, RJ Pomerantz1 and DS Strayer1,2 1The Dorrance H Hamilton Laboratories, Center for Human Virology, Division of Infectious Diseases, Department of Medicine; and 2Department of Pathology, Anatomy and Cell Biology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA, USA Human immunodeficiency virus type I (HIV-1) encodes the SFv-IN was confirmed by Western blotting and several proteins that are packaged into virus particles. Inte- immunofluorescence staining, which showed that Ͼ90% of grase (IN) is an essential retroviral enzyme, which has SupT1 T-lymphocytic cells treated with SV(Aw) expressed been a target for developing agents to inhibit virus repli- the SFv-IN protein without selection. When challenged, cation. In previous studies, we showed that intracellular HIV-1 replication, as measured by HIV-1 p24 antigen expression of single-chain variable antibody fragments expression and syncytium formation, was potently inhibited (SFvs) that bind IN, delivered via retroviral expression vec- in cells expressing SV40-delivered SFv-IN. Levels of inhi- tors, provided resistance to productive HIV-1 infection in bition of HIV-1 infection achieved using this approach were T-lymphocytic cells. In the current studies, we evaluated comparable to those achieved using murine leukemia virus simian-virus 40 (SV40) as a delivery vehicle for anti-IN (MLV) as a transduction vector, the major difference being therapy of HIV-1 infection.
    [Show full text]
  • Evolution of Hepatitis B Serological Markers in HIV Coinfected Patients: a Case Study
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Cadernos Espinosanos (E-Journal) Rev Saúde Pública 2017;51:24 Artigo Original http://www.rsp.fsp.usp.br/ Evolution of hepatitis B serological markers in HIV coinfected patients: a case study Ana Luiza de Castro Conde ToscanoI,II, Maria Cássia Mendes CorrêaII,III I Instituto de Infectologia Emílio Ribas. São Paulo, SP, Brasil II Departamento de Doenças Infecciosas. Faculdade de Medicina. Universidade de São Paulo. São Paulo, SP, Brasil III Instituto de Medicina Tropical de São Paulo. Laboratório de Investigação Médica 52. São Paulo, SP, Brasil ABSTRACT OBJECTIVE: To describe the evolution of serological markers among HIV and hepatitis B coinfected patients, with emphasis on evaluating the reactivation or seroreversion of these markers. METHODS: The study population consisted of patients met in an AIDS Outpatient Clinic in São Paulo State, Brazil. We included in the analysis all HIV-infected and who underwent at least two positive hepatitis B surface antigen serological testing during clinical follow up, with tests taken six months apart. Patients were tested with commercial kits available for hepatitis B serological markers by microparticle enzyme immunoassay. Clinical variables were collected: age, sex, CD4+ T-cell count, HIV viral load, alanine aminotransferase level, exposure to antiretroviral drugs including lamivudine and/or tenofovir. RESULTS: Among 2,242 HIV positive patients, we identified 105 (4.7%) patients with chronic hepatitis B. Follow up time for these patients varied from six months to 20.5 years. All patients underwent antiretroviral therapy during follow-up. Among patients with chronic hepatitis B, 58% were hepatitis B “e” antigen positive at the first assessment.
    [Show full text]
  • USDA-Approved Animal Rabies Vaccines
    United States Department of Agriculture (USDA) Approved Animal Rabies Vaccines Table 1. Rabies Vaccines Licensed and Marketed in the United States, 2016 Age at For use Route of Product Name Produced by Marketed by Dose primary Booster vaccination in inoculation vaccination* A) MONOVALENT (Inactivated) RAB RABVAC 1 Boehringer Boehringer Dogs 1 ml 3 months Annually IM or SC Ingelheim Ingelheim Vetmedica Cats 1 ml 3 months Annually IM or SC Vetmedica Inc Inc License No. 124 RABVAC 3 Boehringer Boehringer Dogs 1 ml 3 months 1 year later & triennially IM or SC Ingelheim Ingelheim Vetmedica Cats 1 ml 3 months 1 year later & triennially IM or SC Vetmedica Inc Inc Horses 2 ml 3 months Annually IM License No. 124 EQUIRAB with Merck Animal Merck Animal Health Horses 1 ml 4 months Annually IM Havlogen Health License No. 165A DEFENSOR 1 Zoetis Zoetis Dogs 1 ml 3 months Annually IM or SC License No. 190 Cats 1 ml 3 months Annually SC DEFENSOR 3 Zoetis Zoetis Dogs 1 ml 3 months 1 year later & triennially IM or SC License No. 190 Cats 1 ml 3 months 1 year later & triennially SC Sheep 2 ml 3 months Annually IM Cattle 2 ml 3 months Annually IM NOBIVAC: 1- Zoetis Merck Animal Health Dogs 1 ml 3 months Annually IM or SC Rabies License No. 190 Cats 1 ml 3 months Annually SC NOBIVAC: 3- Zoetis Merck Animal Health Dogs 1 ml 3 months 1 year later & triennially IM or SC Rabies and 3- License No. 190 Cats 1 ml 3 months 1 year later & triennially SC Rabies CA Sheep 2 ml 3 months Annually IM Cattle 2 ml 3 months Annually IM IMRAB 1 Merial, Inc Merial, Inc Dogs 1 ml 3 months Annually SC License No.
    [Show full text]
  • Medical Update Q&A's
    Medical Update Q&A’s Wednesday, July 15, 2020 Q1: How is TONHC preparing for flu season? Seasonal flu returns each year and infections usually begin in early winter through spring. TONHC has a team that prepares for the flu season each year. A team from epidemiology, public health, pharmacy, nursing, and the medical staff plan, order vaccine, and prepare clinics to deliver immuni- zations. Vaccines will be offered as early as they are available this year to maximize the number of people that get immunized. In a typical year, only about 35-40% of Americans get a flu shot. For the last several years, TONHC has vaccinated between 50-60% of the patients that get their care here and we hope to deliver even more vaccines this year. Despite our vaccination rates being better than most of the country, our aim is to vaccinate as many people in the community as possible. Q2: How will vaccinations be scheduled in COVID-19 environment? Protecting the community from flu this year will be even more important because health care systems could easily become overwhelmed with patients also needing care for COVID-19. Both diseases spread easily, can cause people to miss work, and as we have seen, for some, can be fatal. The flu vaccine is especially helpful to protect people from fatal influenza disease. Each year the strain of flu changes and vaccines have to be manufactured in spring and summer. These generally become available in early autumn. TONHC will give flu shots at all the health centers, in special Flu clinics called “PODs” or “point of delivery” which and be walk-through or drive-through clinics for many people at the same time and can occur at different locations.
    [Show full text]